Our results from in vitro and in vivo experiments showed that Melatonin significantly enhances the cytotoxicity of Neratinib in a panel of HER2+ breast cancer cells harboring PIK3CA mutations known to be less responsive to HER2-targeted agents. The gene discussed is ERBB2; the disease is breast cancer.